X0306 4 2021-07-30 0 0001863294 DA32 Life Science Tech Acquisition Corp. DALS 0001808115 Section 32 Fund 3, LP DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 1 0 1 1 Director by Deputization 0001808116 Section 32 GP 3, LLC 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 1 0 1 1 Director by Deputization 0001722210 Maris William J 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 1 0 1 1 Director by Deputization Class A Common Stock 2021-07-30 4 P 0 800000 10.00 A 800000 D Class A Common Stock 2021-07-30 4 A 0 650000 10.00 A 1450000 I Through DA32 Sponsor LLC Section 32 Fund 3, LP purchased 800,000 shares of the Issuer's Class A common stock for $10.00 per share in the Issuer's initial public offering. This Form 4 is filed jointly by Section 32 Fund 3, LP ("S32 Fund"), Section 32 GP 3, LLC ("S32 GP") and William J. Maris (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. DA32 Sponsor LLC ("Sponsor") purchased 650,000 private placement shares of the Issuer directly from the Issuer for $10.00 per share, concurrently with the Issuer's initial public offering. This purchase was exempted pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended. Sponsor is the record holder of the securities reported herein. As a managing member of Sponsor, S32 Fund may be deemed to beneficially own the securities owned directly by Sponsor. As the general partner of S32 Fund, S32 GP may be deemed to beneficially own the securities owned directly by Sponsor. As the sole Managing Member of S32 GP, William J. Maris may be deemed to beneficially own securities owned directly by Sponsor. See Exhibit 99.1 - Joint Filer Information, which is incorporated herein by reference and describes in further detail the relationships of the Reporting Persons to the Issuer. Henrikki Harsu, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24.1, 24.2 and 24.3 to a Form 3 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on July 27, 2021 by Section 32 Fund 3, LP, Section 32 GP 3, LLC and William J Maris. Steve Kafka, an employee of Section 32 Fund 3, LP, serves as a director of the Issuer. /s/ Henrikki Harsu, Attorney-in-Fact for Section 32 Fund 3, LP 2021-08-03 /s/ Henrikki Harsu, Attorney-in-Fact for Section 32 GP 3, LLC 2021-08-03 /s/ Henrikki Harsu, Attorney-in-Fact for William J Maris 2021-08-03